Clinical trials: aldesleukin
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.
Advanced Breast Cancer, Advanced Lung Cancer
TIL Therapy for Patients With Advanced Solid Tumors
This study is a phase I clinical trial to investigate the safety and tolerability of NEOG-100 in patients with advanced breast cancer and lung cancer.
- Trial name
- NCT06107894
- Testing
- Tumor-infiltrating lymphocytes, IL-2
- Volunteers
- 12 people
- Sponsor
- NeogenTC
Multiple Myeloma
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
This study will find the highest acceptable treatment dose and timing of infusion of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with multiple myeloma.
- Trial name
- NCT02955550
- Testing
- rhIL-2, PNK-007
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celularity Incorporated
Ovarian Cancer Metastatic
OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)
An open label, multi-centre Phase 1/2a study of modified and unmodified autologous Tumour Infiltrating Lymphocytes (TIL) in patients with platinum-resistant ovarian cancer.
- Trial name
- OVSTAR (NCT04389229)
- Testing
- cyclophosphamide, fludarabine, IL-2 (Proleukin)
- Where
- 2 sites in United Kingdom
- Sponsor
- Immetacyte Ltd
HIV Infections
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
The purpose of this study is to see if it is safe and effective to give HIV-positive patients L2-7001 (a type of interleukin-2) plus anti-HIV therapy.
- Trial name
- NCT00002449
- Testing
- Aldesleukin
- Where
- 23 sites in United States
- Volunteers
- 212 people
- Sponsor
- Chiron Corporation
Metastatic Colorectal Cancer, Prostate Cancer Metastatic
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.
- Conditions
- Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced
- Trial name
- ProbeTILity (NCT07255664)
- Testing
- CC-38, Pembrolizumab, Cyclophosphamid
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- CuraCell TX AB
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Solid Tumor
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid tumor and to find appropriate dose for…
- Trial name
- NCT04862767
- Testing
- TASO-001((TGF-β2 targeting anti-sense oligonucleotide), Aldesleukin
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Autotelicbio
Solid Tumor
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor .
- Trial name
- NCT03891706
- Testing
- tumor-specific TCR-T cells, Interleukin-2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Lymphoma, Non-Hodgkin
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
- Trial name
- NCT00045864
- Testing
- Recombinant Human Interleukin-2 and Rituximab
- Where
- 33 sites in United States
- Sponsor
- Chiron Corporation
Renal Cell Carcinoma
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten conjugate therapy (vaccination with EC90 [KLH-FITC] and GPI-0100 adjuvant followed by treatment with EC17 (folate-FITC) in combination…
- Trial name
- NCT00485563
- Testing
- EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Endocyte
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer
CISH Inactivated TILs in the Treatment of NSCLC
A clinical trial to assess the safety and efficacy of genetically-engineered Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- CheckCell-2 (NCT05566223)
- Testing
- Fludarabine, Cyclophosphamide, CISH Inactivated TIL
- Where
- 2 sites in United States
- Sponsor
- Intima Bioscience, Inc.
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06677710
- Testing
- IDP-023, Ocrelizumab, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Indapta Therapeutics, INC.
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Metastatic Melanoma
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
This is a research study to evaluate treatment of metastatic melanoma patients with a combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®) and High Dose Interleukin-2 (abbreviated as HD…
- Trial name
- PROCLIVITY01 (NCT01683188)
- Testing
- vemurafenib + HD IL-2
- Where
- 21 sites in United States
- Volunteers
- 53 people
- Sponsor
- Clinigen, Inc.
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing…
- Conditions
- Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal
- Trial name
- NCT04426669
- Testing
- Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Intima Bioscience, Inc.
Leukemia
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in…
- Trial name
- NCT00003991
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 360 people
- Sponsor
- Maxim Pharmaceuticals
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL…
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Trial name
- NCT03645928
- Testing
- Lifileucel, LN-145, Pembrolizumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 225 people
- Sponsor
- Iovance Biotherapeutics, Inc.
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Cancer, Solid Tumor
ACTolog in Patients With Solid Cancers
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
- Trial name
- ACTolog (NCT02876510)
- Testing
- Fludarabine, Cyclophosphamide, IMA101 product
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Immatics US, Inc.